No Data
Press Release: Structure Therapeutics Strengthens Executive Team With Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
Express News | Structure Therapeutics Strengthens Executive Team With Promotion of Blai Coll, M.d., Ph.d. to Chief Medical Officer and Appointment of Ashley Hall, J.d. as Chief Development Officer
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
16 New GLP-1 Weight-loss Drugs Could Be Launched by 2029: Report
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $86
JMP Securities analyst Jonathan Wolleben maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $86.According to TipRanks data, the analyst has a success
Buy Rating on Structure Therapeutics: Promising GSBR-1290 Clinical Developments and Competitive Market Positioning